Publisher
Springer Berlin Heidelberg
Reference111 articles.
1. Adler LP, Faulhaber PF, Schnur KC et al. (1997) Axillary lymph node metastases: Screening with (F-18)2-deoxy-2fluoro-D-glucose (FDG) PET. Radiology 203:323–327
2. Avril N, Dose J, Jänicke F, Ziegler S et al. (1996) Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxyglucose. J Natl Cancer Inst 88:1204–1209
3. Avril N, Menzel M, Dose J et al. (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16
4. Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in breast cancer. Clin Positron Imag 2:261–271
5. Bakir MA, Eccles SA, Babich JW, Aftab N, Styles JM, Dean CJ, Ott RJ (1992) c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 33:2154–2160